As of January 22, 2026, the Duchenne muscular dystrophy treatment market is identifying as one of the most high-value sectors in rare disease therapeutics, with its 2026 valuation reaching approximately $5.43 billion. The 2026 landscape is defined by a rapid CAGR of 17.1% to 29.4%, fueled by the aggressive commercialization of one-time gene therapies like Elevidys and the transition of...